Oct 20 (Reuters) - Novo Nordisk said on Tuesday its next-generation experimental drug, CagriSema, showed 25% weight loss on ...

Novo has long sold a separate version of oral semaglutide for diabetes under the brand name Rybelsus, which the medicine ...

Todd Engel, 63, said he was diagnosed with nonarteritic anterior ischemic optic neuropathy, NAION, four months after starting ...

Terma joins the Nordic Compass consortium and Euroclear nears a deal as the alliance readies proposals on defense, energy and ...

AstraZeneca (LSE:AZN) has signed an exclusive worldwide research collaboration with insitro focused on MASH and ...

FPT and the Niels Bohr Institute will explore joint quantum research and workshops to support cooperation between Vietnam and ...

With rising incidences of diabetes in India, medications have evolved as has the underlying approach to managing the ...

A genetically confirmed case of Smith-Magenis syndrome in a nine-month-old boy links bilateral high-grade vesicoureteral ...

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster ...

Novo says CagriSema led to 25% average weight loss in women at 68 weeks with menopause subgroup gains; company says further ...

The Danish NOVO Quartet is a shining light in the string quartet firmament, a bright beacon of hope. From the repertoire they chose to their unflagging enthusiasm to the sheer excellence of their ...

Novo Nordisk (NYSE: NVO) presented results from two post hoc analyses of its REDEFINE 1 trial at The Menopause Society 2026 Annual Meeting in San Diego, examining the investigational drug ...